{
    "clinical_study": {
        "@rank": "82286", 
        "arm_group": [
            {
                "arm_group_label": "Omegaven\u2122", 
                "arm_group_type": "Active Comparator", 
                "description": "Omegaven\u2122 (approval number:54750 Swissmedic)- 100ml intravenously. The first dose (Omegaven\u2122 or placebo) is administered in the evening before surgery, the second dose at the beginning of anesthesia. The maximum infusion rate must be adjusted to bodyweight (0.5 ml Omegaven\u2122/kg/hour)."
            }, 
            {
                "arm_group_label": "NaCl 0.9%", 
                "arm_group_type": "Placebo Comparator", 
                "description": "100ml of saline is used as a placebo comparator and administered as described above."
            }
        ], 
        "brief_summary": {
            "textblock": "To study the efficacy and safety of intravenous Omegaven\u2122 (vs. Placebo) in reducing\n      postoperative morbidity and mortality after major liver resection."
        }, 
        "brief_title": "Effects of Omega-3 Fatty Acids on Outcome After Major Liver Resection", 
        "completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Major Liver Surgery", 
        "detailed_description": {
            "textblock": "With two single doses of Omegaven (pre- and postoperatively) we aim to reduce postoperative\n      complications measured by the CCI (Comprehensive Complication Index) and the Clavien Dindo\n      classification of surgical complications. The study will include adults (more than 18 years)\n      patients requiring liver resection of at least 1 segment or multiple wedge resections (\u22653)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Requiring liver resection of at least 1 segment or multiple wedge resections (=3)\n\n          -  > 18 years of age\n\n          -  No coagulopathy (INR < 1.2, platelets >150'000 x10E3/\u00b5l)\n\n          -  Understands local language\n\n        Exclusion criteria:\n\n          -  Liver resections <1 segment\n\n          -  Wedge resections (<3)\n\n          -  Liver cirrhosis\n\n          -  Coagulopathy (INR > 1.2, platelets < 150'000 x10E3/\u00b5l)\n\n          -  Hypertriglyceridemia (> 5.0 mmol/l)\n\n          -  Hypersensitivity or allergy to Omegaven\u2122 or any fish oil or lipid emulsions\n\n          -  Known allergy to egg protein\n\n          -  Pregnancy\n\n          -  Nursing women\n\n          -  Renal failure(estimated GFR < 30 ml/min/1.73m2)\n\n          -  Medication impairing platelets aggregation\n\n          -  Cannot understand local language"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "258", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01884948", 
            "org_study_id": "Omegaven - Zurich"
        }, 
        "intervention": {
            "arm_group_label": "Omegaven\u2122", 
            "intervention_name": "Omegaven\u2122", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "at least 1 segment", 
            "multiple wedge resections (\u22653)"
        ], 
        "lastchanged_date": "June 3, 2014", 
        "link": {
            "description": "Omegaven", 
            "url": "http://www.kompendium.ch/mpro/mnr/8980/html/de"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Zurich", 
                    "country": "Switzerland", 
                    "state": "ZH", 
                    "zip": "8091"
                }, 
                "name": "University Hospital Zurich, Visceral and Transplantation Surgery"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Switzerland"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind Study of the Effects of Omega-3 Fatty Acids (Omegaven\u2122) on Outcome After Major Liver Resection", 
        "overall_contact": {
            "email": "Michael.Linecker@usz.ch", 
            "last_name": "Michael Linecker, MD", 
            "phone": "0041 442553300"
        }, 
        "overall_contact_backup": {
            "email": "clavien@access.uzh.ch", 
            "last_name": "Pierre Alain Clavien, MD PhD", 
            "phone": "0041 442553300"
        }, 
        "overall_official": {
            "affiliation": "University Hospital Zurich, Visceral and Transplantation Surgery", 
            "last_name": "Pierre Alain Clavien, MD PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Switzerland: Swissmedic", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Complications will be assessed using the Comprehensive Complication Index (CCI) and the Clavien-Dindo complication classification.", 
            "measure": "Postoperative complications", 
            "safety_issue": "No", 
            "time_frame": "1 month after hospital discharge"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01884948"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "University of Zurich", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Zurich", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "June 2014"
    }
}